NCT07333300

Brief Summary

This is a prospective, exploratory, double-blind, single-visit internal validation study designed to evaluate neurosensory responses using electroencephalography head band (EEG) in adult subjects with mild to moderate atopic dermatitis (AD) following a single topical application of marketed product compared with placebo (water application).

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
20

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Nov 2025

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 14, 2025

Completed
1 day until next milestone

First Submitted

Initial submission to the registry

November 15, 2025

Completed
16 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2025

Completed
1 month until next milestone

First Posted

Study publicly available on registry

January 12, 2026

Completed
Last Updated

August 5, 2026

Status Verified

November 1, 2025

Enrollment Period

17 days

First QC Date

November 15, 2025

Last Update Submit

August 4, 2026

Conditions

Keywords

atopic dermatitis

Outcome Measures

Primary Outcomes (1)

  • To measure neurosensory responses associated with pain, pruritus, and discomfort in subjects with atopic dermatitis.

    To measure the changes in the * Alpha Wavelength activity * Beta Wavelength activity * Theta Wavelength activity It will be measured through MUSE Biosensing Headband. The headband will be applied over the subjects in head area and the electrodes will help in detection of the wavelength.

    • Baseline (before application of the test product) • During Stimulus Induction • Post-stimulus induction (test product use) at T-30 minutes.

Study Arms (2)

Arm 1 - Test Product- CeraVe Moisturizing Lotion

EXPERIMENTAL

Arm 1 (Test Product): Subjects in this group will receive the marketed product, applied topically as per the study procedure.

Other: Marketed Test Product

Placebo Comparator: Arm 2

EXPERIMENTAL

Arm 2 (Placebo Control): Subjects in this group will receive a placebo (water application), in which no active ingredient will be added. The placebo will be identical in appearance and texture to the test product to maintain blinding.

Other: Placebo

Interventions

Topical Application Frequency: Single Application. Spread the cream in the same direction and avoid scratching after application.

Arm 1 - Test Product- CeraVe Moisturizing Lotion
PlaceboOTHER

Topical Application Frequency : Single Application Spread the cream in the same direction and avoid scratching after application.

Placebo Comparator: Arm 2

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age: 18 to 65 years (both inclusive) at the time of consent having mild to moderate atopic dermatitis. 2. Sex: Healthy male and non-pregnant/non-lactating females. 3. Females of childbearing potential must have a self-reported negative pregnancy test. 4. Subject are generally in good health. 5. Subjects who agree to come to the facility with clean and dry scalp and hair 6. Subjects with mild to moderate Atopic Dermatitis determined by Eczema
  • Area and Severity Index (EASI) score with moderate erythema (redness:
  • score 2) and mild scratch mark (scratching: score 1) will be enrolled into the study 7. Subjects are not allowed to participate in any other study until this study is complete. 8. Subjects willing and able to follow the study directions. 9. Having childbearing potential, is practicing and agrees to maintain an established method of birth control (IUD, hormonal implant device/ injection, regular use of birth control pills or patch, diaphragm, condoms with spermicide or sponge with spermicidal jelly, cream or foam,partner vasectomy or abstinence). Females will be considered as nonchildbearing potential if they are surgically sterile, have been postmenopausal for at least 1 year or have had a tubal ligation. 10. Subjects willing to give written consent through subject information sheet. 11. Subjects have not participated in a similar investigation in the past three months. 12. Subjects willing to use test product throughout the study period.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

NovoBliss Research

Ahmedabad, Gujarat, 382481, India

Location

MeSH Terms

Conditions

Dermatitis, Atopic

Condition Hierarchy (Ancestors)

Skin Diseases, GeneticGenetic Diseases, InbornCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesDermatitisSkin DiseasesSkin and Connective Tissue DiseasesSkin Diseases, EczematousHypersensitivity, ImmediateHypersensitivityImmune System Diseases

Study Officials

  • Nayan Patel

    NovoBliss Research Private Limited

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
OTHER
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 15, 2025

First Posted

January 12, 2026

Study Start

November 14, 2025

Primary Completion

December 1, 2025

Study Completion

December 1, 2025

Last Updated

August 5, 2026

Record last verified: 2025-11

Data Sharing

IPD Sharing
Will not share

Locations